GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
NCT06961344 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect78/100
StatusTERMINATED
PhasePHASE2
Lead sponsorTisento Therapeutics
Last update2026-10-30
Public-record facts
| Intervention | zagociguat 15mg (DRUG) |
|---|---|
| Condition | Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome) |
| Enrollment | 37 |
| Why stopped | On 5 October 2026 the study was terminated based on results from the parent study, which did not meet its primary or secondary efficacy endpoints. The decision was not related to a safety. |
| Results posted | No / not indicated |
Why Beacon surfaced it
- The record is terminated and was updated 2026-10-30.
- It is an interventional PHASE2 study with a named drug intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT06961344. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.